
    
      This is a prospective, open-label, single-arm, historically controlled, multi-center Phase
      III study to assess the pharmacokinetics and safety of Immune Globulin Intravenous (Human)
      GC5107 in pediatric subjects aged â‰¥ 2 years and < 12 years with PHID.

      Subjects will receive intravenous infusions of the investigational product at the same dose
      and interval as used for their previous Immunoglobulin intravenous (IGIV) maintenance
      therapy. GC5107 will be infused every 21 or 28 days for a period of 12 months.
    
  